Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

Share Price is delayed by 15 minutes
Get Live Data
14.50    0.00 (0.00%)
Bid:
14.00
Ask:
15.00
Spread: 1.00 (7.143%)
Market Cap: £11.97m
FIPP Live PriceLast checked at - London Stock Exchange

Intraday Frontier Ip Share Chart

Elute Intelligence appoints Steve Cable as CEO

14 Oct 2022 07:00

RNS Number : 8774C
Frontier IP Group plc
14 October 2022
 

REACH

AIM: FIPP

14 October 2022

 

Frontier IP Group plc

("Frontier IP" or the "Group")

 

 

Portfolio news - Elute Intelligence appoints Steve Cable as Chief Executive Officer

 

Frontier IP, a specialist in commercialising intellectual property, today announces that portfolio company Elute Intelligence Holdings Limited ("Elute" or the "Company") has appointed Steve Cable as Chief Executive Officer. Steve will guide the organisation through the development of existing Elute products with an emphasis on product alignment, market traction and commercial growth.

 

Steve has more than 25 years' experience in building businesses at start-ups, mid-size firms and large companies. He has worked with software solutions in Artificial Intelligence, Search, Professional Services Automation, Enterprise Resource Planning, and Identity Management across a wide diversity of sectors.

 

His experience of leading strategy, positioning solutions, and penetrating existing markets, is a core requirement for Elute. This was recently demonstrated where he was part of leadership team at CMap Software. The Company went from being a relatively unknown start up to industry leader with more than £4m annual recurring revenues, leading to a private equity investment in December 2019.

 

The Elute technology is based on encoding forensic linguistic principles in software. The core competency enables documents to be read in a manner similar to humans, but by a computer at great speed. It is possible for the system to 'read' millions of documents in seconds and identify the documents that are of greatest relevance. The software can clearly show the user why documents are relevant, a marked difference to artificial intelligence or semantic search approaches used by competing products.

 

Other complementary competencies allow rapid detailed comparison of text in documents, authorship detection for plagiarism and collusion detection, and an ability to automatically summarise documents. While Elute's current products are English language based, the functionality is not language dependent and therefore the products could in principle be applied to a wide range of languages including English, Russian, Arabic and Chinese.

 

The technology is live, proven, and trusted by organisations such as UCAS and the Open University.

 

Steve Cable, Elute Chief Executive Officer, said: "I joined Elute due to the many possible applications of the technology. I've had the benefit of working in two of the UK's leading SaaS search software providers, so I immediately recognised the possibilities. In the short time I've been on board we have made big strides and we expect to be able to launch a new differentiated product very soon. My primary aim is taking this technology to market, gaining user feedback, and monetising as soon as possible." 

 

Frontier IP Chief Executive Neil Crabb said: "Elute has the potential to transform the way in which we search and compare text stored in large, complex, and unstructured datasets. We are very pleased that Steve has been appointed Elute's Chief Executive. He has already made great progress since he joined the Company, and we are looking forward to working with him as CEO as he takes it forward to success."

 

ENQUIRIES

Frontier IP Group Plc

T: 020 7332 2338

Neil Crabb, Chief Executive

Andrew Johnson, Communications and investor relations

andrew.johnson@frontierip.co.uk

Company website: www.frontierip.co.uk

neil@frontierip.co.uk

M: 07464 546 025

Allenby Capital Limited (Nominated Adviser)

T: 0203 328 5656

Nick Athanas / George Payne

 

ABOUT FRONTIER IP

Frontier IP unites science, finance and industry by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

About Reach announcements

This is a RNS Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFFFEDDEESESS
Date   Source Headline
15th May 20187:00 amRNSPalintest launches Molendotech bathing water test
18th Apr 20184:09 pmRNSHolding(s) in Company
9th Apr 20188:25 amRNSIncreased Equity Holding in Fieldwork Robotics
27th Mar 20187:00 amRNSHALF-YEAR RESULTS, 6 MONTHS TO 31 DECEMBER 2017
26th Mar 20187:00 amRNSTeam Expansion and London Office
19th Feb 20187:00 amRNSPortfolio News - Molendotech Secures First Funding
29th Jan 20187:00 amRNSCapital Markets Day
29th Jan 20187:00 amRNSPortfolio News - Molendotech Collaboration
18th Dec 20177:00 amRNSCapital Markets Day
7th Dec 201711:50 amRNSResult of AGM
8th Nov 20177:00 amRNSPosting of Annual Report and Notice of AGM
30th Oct 20175:15 pmRNSHolding(s) in Company
30th Oct 201712:00 pmRNSPortfolio News PulsiV Granted Two US Patents
24th Oct 20177:00 amRNSFinal Results
9th Oct 20177:00 amRNSExscientia Wins Emerging Biotech Company Award
28th Sep 20177:00 amRNSExscientia announces investment from Evotec
25th Sep 20171:12 pmRNSHolding(s) in Company
20th Sep 20177:00 amRNSAlusid extends range at London Design Festival
7th Sep 20177:00 amRNSCSI launches novel sensor system at IFA Berlin
8th Aug 20177:00 amRNSNew Portfolio Company - The Vaccine Group
28th Jul 20173:26 pmRNSHolding(s) in Company
20th Jul 20177:00 amRNSPortfolio News- Nandi Proteins Limited Fundraising
11th Jul 20174:38 pmRNSHolding(s) in Company
5th Jul 20177:00 amRNSNew Portfolio Company - MolEndoTech
3rd Jul 20177:00 amRNSExscientia announces major GSK collaboration
11th May 20177:00 amRNSGrant of Options
9th May 201712:05 pmRNSRoyal Society of Chemistry Nominations
9th May 201711:25 amRNSExscientia announces major Sanofi collaboration
30th Mar 20177:00 amRNSHalf-Year Results for the 6 Months to 31 Dec 2016
24th Mar 20174:33 pmRNSHolding(s) in Company
23rd Mar 20173:27 pmRNSHolding(s) in Company
23rd Mar 20173:26 pmRNSHolding(s) in Company
23rd Mar 20173:25 pmRNSHolding(s) in Company
17th Mar 201712:10 pmRNSPlacing to raise £3 million
8th Feb 20177:00 amRNSChange of Adviser
23rd Dec 201611:45 amRNSResult of AGM
7th Dec 20167:00 amRNSNew Portfolio Company - Tarsis Technology Limited
28th Nov 20167:00 amRNSPosting of Annual Report and Notice of AGM
21st Nov 20167:00 amRNSAudited final results for year ended 30 June 2016
4th Nov 201611:00 amRNSALUSID Wins Prestigious IChemE Award
14th Sep 201611:50 amRNSAgreement with FCT, Universidade NOVA de Lisboa
5th Sep 20167:00 amRNSNandi Proteins Participant in £1m Funding Award
27th Apr 20167:00 amRNSex scientia Limited - Partnership with Evotec AG
11th Apr 20163:31 pmRNSHolding(s) in Company
7th Apr 20167:05 amRNSHolding(s) in Company
7th Apr 20167:00 amRNSGrant of Options
31st Mar 20168:30 amRNSHolding(s) in Company
30th Mar 20169:00 amRNSHolding(s) in Company
24th Mar 20167:00 amRNSEquity Placing raising £1.0M & Total Voting Rights
9th Mar 20167:00 amRNSHalf-year results for the 6 months to 31 Dec 2015

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.